Ser842

Site Information
KKVtRAFsFsktPKR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3212784

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 )
Disease tissue studied:	breast cancer ( 2 ) , breast ductal carcinoma ( 2 ) , breast cancer, triple negative ( 2 ) , gastric cancer ( 16 , 17 , 18 ) , gastric carcinoma ( 16 , 17 , 18 ) , liver cancer, surrounding tissue ( 19 ) , lung cancer ( 3 , 7 , 20 ) , non-small cell lung cancer ( 7 , 20 ) , non-small cell lung cancer, surrounding tissue ( 21 ) , non-small cell lung adenocarcinoma ( 3 ) , ovarian cancer ( 2 ) , melanoma skin cancer ( 15 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 14 ) , breast ( 2 ) , H2009 (pulmonary) ( 7 ) , H2077 (pulmonary) ( 7 ) , H2887 (pulmonary) ( 7 ) , H322M (pulmonary) ( 7 ) , HCC1359 (pulmonary) ( 7 ) , HCC2279 (pulmonary) ( 7 ) , HCC366 (pulmonary) ( 7 ) , HCC4006 (pulmonary) ( 7 ) , HCC78 (pulmonary) ( 7 ) , HeLa (cervical) ( 6 , 22 ) , HOP62 (pulmonary) ( 7 ) , Jurkat (T lymphocyte) ( 4 , 9 , 10 , 11 , 12 , 13 ) , K562 (erythroid) ( 6 ) , liver ( 19 ) , LOU-NH91 (squamous) ( 7 ) , lung ( 3 , 20 , 21 ) , MKN-45 (gastric) ( 16 , 17 , 18 ) , NCI-H1395 (pulmonary) ( 7 ) , NCI-H1568 (pulmonary) ( 7 ) , NCI-H2030 (pulmonary) ( 7 ) , NCI-H2172 (pulmonary) ( 7 ) , NCI-H322 (pulmonary) ( 7 ) , NCI-H460 (pulmonary) ( 7 ) , NCI-H520 (squamous) ( 7 ) , NCI-H647 (pulmonary) ( 7 ) , ovary ( 2 ) , PC9 (pulmonary) ( 7 ) , skin ( 15 ) , Vero E6-S ('epithelial, kidney') ( 1 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
3	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
4	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
5	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
6	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
7	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
8	Rikova K (2012) CST Curation Set: 13916; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 2/treated; Disease: -; SILAC: -; Curated Info
9	Mulhern D (2011) CST Curation Set: 13068; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]F Curated Info
10	Mulhern D (2011) CST Curation Set: 13069; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]F Curated Info
11	Mulhern D (2011) CST Curation Set: 13070; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]F Curated Info
12	Mulhern D (2011) CST Curation Set: 13071; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]F Curated Info
13	Mulhern D (2011) CST Curation Set: 13072; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631 Curated Info
14	Guo A (2010) CST Curation Set: 6258; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631 Curated Info
15	Tucker M (2010) CST Curation Set: 9780; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
16	Moritz A (2010) CST Curation Set: 9281; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'\|\|' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
17	Moritz A (2010) CST Curation Set: 9236; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
18	Possemato A (2010) CST Curation Set: 9174; Year: 2010; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
19	Tucker M (2010) CST Curation Set: 8915; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
20	Rikova K (2009) CST Curation Set: 8541; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
21	Rikova K (2009) CST Curation Set: 8531; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
22	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info